These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29683789)

  • 1. DNA Repair Deficiency and Immunotherapy Response.
    Mouw KW; D'Andrea AD
    J Clin Oncol; 2018 Jun; 36(17):1710-1713. PubMed ID: 29683789
    [No Abstract]   [Full Text] [Related]  

  • 2. Family history of cancer and DNA damage response genes: Two sides of the same coin?
    Cortellini A; Bersanelli M; Ficorella C; Buti S
    Thorac Cancer; 2019 Feb; 10(2):401. PubMed ID: 30536563
    [No Abstract]   [Full Text] [Related]  

  • 3. DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Zhu Z; Chen P; Yan Z
    Thorac Cancer; 2018 Aug; 9(8):901-903. PubMed ID: 29932513
    [No Abstract]   [Full Text] [Related]  

  • 4. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can radiomics personalise immunotherapy?
    El Naqa I; Ten Haken RK
    Lancet Oncol; 2018 Sep; 19(9):1138-1139. PubMed ID: 30120042
    [No Abstract]   [Full Text] [Related]  

  • 6. DDR signature to predict response to ICI.
    Romero D
    Nat Rev Clin Oncol; 2018 Jun; 15(6):346. PubMed ID: 29593260
    [No Abstract]   [Full Text] [Related]  

  • 7. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
    Zhu XR; Zheng LZ
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
    Luo M; Fu L
    Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply to S. Zhang et al.
    Teo MY; Seier K; Ostrovnaya I; Rosenberg JE
    J Clin Oncol; 2018 Oct; 36(30):3057-3058. PubMed ID: 30183465
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy: Benefit with anti-PD-L1.
    Romero D
    Nat Rev Clin Oncol; 2017 Feb; 14(2):70-71. PubMed ID: 28031557
    [No Abstract]   [Full Text] [Related]  

  • 11. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis.
    Sebaratnam DF; Rodríguez Bandera AI; Lowe PM
    JAMA Dermatol; 2018 Jan; 154(1):112-113. PubMed ID: 29167874
    [No Abstract]   [Full Text] [Related]  

  • 13. Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis.
    Manson G; Marabelle A; Houot R
    JAMA Dermatol; 2018 Jan; 154(1):113. PubMed ID: 29167871
    [No Abstract]   [Full Text] [Related]  

  • 14. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
    Patel J; Crawford JM
    Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer.
    Pearson AT; Sweis RF
    JAMA Oncol; 2019 May; 5(5):743. PubMed ID: 30896751
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply.
    Ferrara R; Caramella C; Besse B
    JAMA Oncol; 2019 May; 5(5):744. PubMed ID: 30896761
    [No Abstract]   [Full Text] [Related]  

  • 17. Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?
    Bourlon MT; Velázquez HE; Luna-Santiago R; Vázquez-Manjarrez S; Bourlon C
    Oncology (Williston Park); 2018 Feb; 32(2):64-8. PubMed ID: 29492946
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics of Immunobiology in the Tumor Microenvironment- Development of Immunotherapies.
    Song J; Teng Z; Cao W
    J Immunol Res; 2019; 2019():1513964. PubMed ID: 31019979
    [No Abstract]   [Full Text] [Related]  

  • 19. Commentary on Pharmacometrics for Immunotherapy.
    Garrido MJ; Berraondo P; Trocóniz IF
    CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):8-10. PubMed ID: 27997736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis.
    Banerjee D; Monaghan S; Zhao R; Walsh T; Palmisciano A; Phillips GS; Opal S; Levy MM
    Crit Care; 2018 Jun; 22(1):146. PubMed ID: 29875013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.